Semax

Semax occupies an unusual position in the peptide world: it's one of the very few research peptides that is actually an approved prescription drug — just not in most Western countries. In Russia, it has been on the official list of vital and essential medicines since 2011 and is used in hospital settings for stroke recovery, traumatic brain injury, and cognitive impairment. That history of clinical use gives it a somewhat different evidence base than peptides that exist only as research chemicals.

It was developed in the 1980s and 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, as part of a programme looking at fragments of ACTH — a hormone your body uses to manage stress response. Researchers found that a particular 7-amino-acid sequence from the middle of the ACTH molecule had strong neuroprotective and cognitive effects without the hormonal side effects of the full molecule. That sequence became Semax.

The main mechanism that researchers have focused on is BDNF — brain-derived neurotrophic factor. Semax rapidly raises BDNF and TrkB (its receptor) levels in the hippocampus, the brain region most central to memory and learning. BDNF is often described as fertiliser for the brain; higher levels are associated with better memory, faster learning, and more resilience against neurodegenerative disease. Semax also activates dopaminergic and serotonergic pathways, which likely explains the improvements in focus, motivation, and mood that users frequently report.

Intranasal administration is the standard route — a nasal spray that delivers the peptide directly to the brain via the olfactory pathway, bypassing the bloodstream and avoiding the degradation that would happen with oral ingestion. Outside Russia, Semax exists in a grey area — it's not approved by the FDA or most European regulators, but it's not explicitly scheduled as a controlled substance in most jurisdictions either.